Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopenia

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 2, 2012, Pages 286-290

  Akahoshi, Tomohiko ^a   Tomikawa, Morimasa ^a   Kawanaka, Hirofumi ^a   Furusyo, Norihiro ^a   Kinjo, Nao ^a   Tsutsumi, Norifumi ^a   Nagao, Yoshihiro ^a   Hayashi, Jun ^a   Hashizume, Makoto ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Hepatitis C virus cirrhosis; Hypersplenism; Laparoscopic splenectomy; Peginterferon; Ribavirin

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; WARFARIN;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HAND ASSISTED LAPAROSCOPY; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; HYPERSPLENISM; LAPAROSCOPIC SURGERY; LEUKOCYTE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PORTAL VEIN THROMBOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 84856193748     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06870.x     Document Type: Article

References (29)

1. Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann. Intern. Med. 1999; 131: 174-81.
2. Bruno S, Stroffolini T, Colombo M etal. Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
3. Ikeda K, Saitoh S, Arase Y etal. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
4. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124: 1711-19, Review.
5. Hoofnagle JH. Thrombocytopenia during interferon alfa therapy. JAMA 1991; 266: 849.
6. Soza A, Everhart JE, Ghany MG etal. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 1273-9.
7. Hashizume M, Sugimachi K, Kitano S etal. Laparoscopic splenectomy. Am. J. Surg. 1994; 167: 611-14.
8. Hashizume M, Tomikawa M, Akahoshi T etal. Laparoscopic splenectomy for portal hypertension. Hepatogastroenterology 2002; 49: 847-52.
9. Kawanaka H, Akahoshi T, Kinjo N etal. Technical standardization of laparoscopic splenectomy harmonized with hand-assisted laparoscopic surgery for patients with liver cirrhosis and hypersplenism. J. Hepatobiliary Pancreat. Surg. 2009; 16: 749-57.
10. Kercher KW, Carbonell AM, Heniford BT, Matthews BD, Cunningham DM, Reindollar RW. Laparoscopic splenectomy reverses thrombocytopenia in patients with hepatitis C cirrhosis and portal hypertension. J. Gastrointest. Surg. 2004; 8: 120-6.
11. Akahoshi T, Tomikawa M, Korenaga D etal. Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism. Surg. Endosc. 2010; 24: 680-5.
12. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis; diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
13. Furusyo N, Kajiwara E, Takahashi K etal.; Kyushu University Liver Disease Study (KULDS) Group. Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Group. J. Gastroenterol. Hepatol. 2008; 23: 1094-104.
14. Hayashi PH, Mehia C, Joachim Reimers H, Solomon HS, Bacon BR. Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis. J. Clin. Gastroenterol. 2006; 40: 740-4.
15. McHutchison JG, Everson GT, Gordon SC etal.; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009; 360: 1827-38.
16. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
17. McCarthy JJ, Li JH, Thompson A etal. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
18. Murata K, Shiraki K, Sugimoto K etal. Splenectomy enhances liver regeneration through tumor necrosis factor (TNF)-alpha following dimethylnitrosamine-induced cirrhotic rat model. Hepatogastroenterology 2001; 48: 1022-7.
19. Akahoshi T, Hashizume M, Tanoue K etal. Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor beta-1. J. Gastroenterol. Hepatol. 2002; 17: 59-65.
20. Hézode C, Forestier N, Dusheiko G etal.; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009; 360: 1839-50.
21. Okamura S, Sakai T, Yoshikai H etal. Case of overwhelming postsplenectomy infection (OPSI) with chronic hepatitis type C during peginterferon/ribavirin combination therapy. Nippon. Shokakibyo. Gakkai. Zasshi 2009; 106: 411-17.
22. Hadem J, Cornberg M, Hauptmann C, Süttmann U, Manns MP, Wedemeyer H. Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C-do not miss vaccination before starting therapy. Z. Gastroenterol. 2008; 46: 880-2.
23. Sangro B, Bilbao I, Herrero I etal. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology 1993; 18: 309-14.
24. Alwmark A, Bengmark S, Gullstrand P, Joelsson B, Lundequist A, Owman T. Evaluation of splenic embolization in patients with portal hypertension and hypersplenism. Ann. Surg. 1982; 196: 518-24.
25. Noguchi H, Hirai K, Aoki Y, Sakata K, Tanikawa K. Changes in platelet kinetics after a partial splenic arterial embolization in cirrhotic patients with hypersplenism. Hepatology 1995; 22: 1682-8.
26. Tomikawa M, Akahoshi T, Sugimachi K etal. Laparoscopic splenectomy may be a superior supportive intervention for cirrhotic patients with hypersplenism. J. Gastroenterol. Hepatol. 2010; 25: 397-402.
27. Vujic I, Lauver JW. Severe complications from partial splenic embolization in patients with liver failure. Br. J. Radiol. 1981; 54: 492-5.
28. Hayashi H, Beppu T, Okabe K, Masuda T, Okabe H, Baba H. Risk factors for complications after partial splenic embolization for liver cirrhosis. Br. J. Surg. 2008; 95: 744-50.
29. McHutchison JG, Dusheiko G, Shiffman ML etal.; TPL102357 Study Group. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N. Engl. J. Med. 2007; 357: 2227-36.